Keyword: Amneal Pharmaceuticals
Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast.
Already facing thousands of civil suits, Johnson & Johnson and Teva could be facing a criminal investigation into their opioid businesses.
At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.
Amneal CEO Chintu Patel expects to expand a plant in New York and add 400 employees as a merger with Impax nears.
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
With branded and generic sales near the top of the pack, Novartis holds somewhat of a unique position. The drugmaker turned up fourth in FiercePharma’s review of top drugmakers by overall revenue last year, and its Sandoz outfit landed in second place for generic sales.